Androgens and Ovarian Function: Translation from Basic Discovery Research to Clinical Impact

May 2019 in “ Journal of Endocrinology ”

Kirsty A Walters, Valentina Rodriguez Paris, Ali Aflatounian, David J. Handelsman

androgens androgen receptor AR Dehydroepiandrosterone DHEA testosterone Letrozole aromatase inhibitor recombinant luteinizing hormone rLH recombinant human chorionic gonadotrophin rhCG polycystic ovary syndrome PCOS Androgen Receptor Knockout ARKO

Studysummary This review summarizes research on androgens' roles in female reproductive function, noting their impact on IVF outcomes and the development of PCOS, and highlights the need for mechanism-based therapies.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on joe.bioscientifica.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

research The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

767 citations , September 2016 in “Human Reproduction”

This review analyzes the reported prevalence of polycystic ovary syndrome (PCOS) based on different diagnostic criteria but does not provide new clinical results.

research Comparison of Spironolactone and Spironolactone Plus Metformin in the Treatment of Polycystic Ovary Syndrome

10 citations , September 2015 in “Gynecological Endocrinology”

In this study, spironolactone and spironolactone plus metformin both significantly reduced hirsutism scores in women with PCOS, but the combination therapy was not more effective than spironolactone alone regarding BMI, hormone levels, or insulin resistance.

research Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline

1265 citations , October 2013 in “The Journal of Clinical Endocrinology and Metabolism”

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

research Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline

1744 citations , August 2006 in “The Journal of Clinical Endocrinology and Metabolism”

This review discusses definitions of polycystic ovary syndrome and reports no new clinical results; the authors support using modified 1990 NIH criteria and acknowledge ongoing evolution as research advances.

research The Benefits of Finasteride for Hirsute Women with Polycystic Ovary Syndrome or Idiopathic Hirsutism

40 citations , January 2003 in “Gynecological Endocrinology”

This study found that finasteride significantly reduced hirsutism in women with idiopathic hirsutism or polycystic ovary syndrome over six months, suggesting its potential effectiveness for this condition.

Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double-Blind, Placebo-Controlled Trial

research Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double-Blind, Placebo-Controlled Trial

94 citations , January 2000 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.

A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism

research A Prospective Randomized Trial Comparing Low Dose Flutamide, Finasteride, Ketoconazole, and Cyproterone Acetate-Estrogen Regimens in the Treatment of Hirsutism

113 citations , April 1999 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.